Form D · Pharmaceuticals

Aspargo Laboratories, Inc.

Englewood Cliffs, NJ · CIK 0001805092

Offering snapshot reported Dec 5, 2022 · SEC filing

Reported sold
$290K
Offering amount: $15M
Investors reported
0
Form D · investor count
Minimum accepted
$40K
Reported outside-investor minimum
First sale
Nov 28, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 5, 2022Initial$290,000No comparison0SEC filing
Mar 28, 2022Initial$1,531,998No comparison19SEC filing
Oct 15, 2020Amendment$7,900,000$7,665,000vs Mar 3, 2020290SEC filing
Jul 28, 2020Amendment$2,511,900$2,276,900vs Mar 3, 202088SEC filing
Mar 3, 2020Initial$235,000No comparison6SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$20.3K
Finders' fees
$0
Form D file number
021-466492

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Axiom Capital Management, Inc.26580Eric Miller
Newbridge Securities Corporation104065Gene Abrams

Source: Form D, filed Dec 5, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Fred Biehl Director
Michael Demurjian Executive
Michael Rice Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
550 Sylvan Avenue
Englewood Cliffs, NJ, 07632